A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Exclusion Criteria

• •1. Patients that require urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression；
• •2. Patients that have active hemolytic anemia；
• •3. Patients who have uncontrollable infectious diseases within 2 weeks before enrollment;
• •4. Patients with human immunodeficiency virus (HIV) antibody seropositive;
• •5. Active infection of Hepatitis B virus and / or hepatitis C virus;
• •6. Patients with any residual intracranial implants；
• •7. Coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system；
• •8. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease)；
• •9. Concurrent opportunistic infections；
• •10. Concurrent systemic steroid therapy；
• •11. History of severe immediate hypersensitivity reaction to any of the agents used in this study；
• •12. Women of child-bearing potential who are pregnant or breastfeeding；
• •13. Patients with cardiac atrial or cardiac ventricular lymphoma involvement；
• •14. Other anti-neoplastic investigational agents currently or within 30 days prior to start of the treatment；
• •15. Psychiatric patients;
• •16. Previous treatment with any gene therapy products.